Pacific Biosciences Of California (PACB) Net Cash Flow Growth (5y) (2015 - 2026)
Pacific Biosciences Of California (PACB) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Pacific Biosciences Of California | 419.38 Mn | 182.51 Mn | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.98% |
| Mar 31, 2026 | -14.97% |
| Dec 31, 2025 | -11.91% |
| Sep 30, 2025 | -42.15% |
| Jun 30, 2025 | 30.92% |
| Mar 31, 2025 | -39.67% |
| Dec 31, 2024 | -45.59% |
| Sep 30, 2024 | -58.23% |
| Jun 30, 2024 | 36.20% |
| Mar 31, 2024 | -48.96% |
| Dec 31, 2023 | -60.66% |
| Sep 30, 2023 | 63.69% |
| Jun 30, 2023 | -127.12% |
| Mar 31, 2023 | 26.28% |
| Dec 31, 2022 | 33.19% |
| Sep 30, 2022 | 10.63% |
| Jun 30, 2022 | -78.38% |
| Mar 31, 2022 | -35.69% |
| Dec 31, 2021 | 51.06% |
| Jun 30, 2021 | -152.59% |